参考文献/References:
1 Ballantyne CM, Hoogeveen RC, Bang H. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities(ARIC)study. Arch Intern Med,2005,165(21):2479-2484.
2 Elkind MS, Leon V, Moon YP. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and afterstroke and myocardial infarction. Stroke,2009,40(10):3233-3237.
3 Knauer C, Knauer K, Müller S. A biochemical marker panel in MRI-proven hyperacute ischemic stroke-a prospective study. BMC Neurol,2012,8:12-14.
4 中华医学会神经病学分会脑血管病学组 急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010.中华神经科杂志,2010,43(2)146-152.
5 Adams HP Jr, Bendixen BH, Kappelle LJ, et al. the TOAST investigators. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke,1993,24(1):35-41.
6 Oei HH, vander Meer IM, Hofinan A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke:the Rotterdam stidy. Circulation, 2005, 111(5): 570-575.
7 钟 萍,吴丹红,吴计划,等.血清脂蛋白相关磷脂酶A2和超敏C-反应蛋白水平与大动脉粥样硬化性脑梗死关系的临床研究. 中华临床医师杂志,2012,6(4):924-927.
8 HoyA, Leininger-Muller B, Poirier O,et al. Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis,2003,167(2):223-230.
9 Palm F1, Lahdentausta L, Sorsa T. Biomarkers of periodontitis and inflammation in ischemic stroke: A case-control study. Innate Immun. 2013,20(5):511-518.
10 Montaner J, Rovira A, Molina CA, et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab,2003,23(12):1403-1407.
11 Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-
9 reduces infarct size. Stroke,1998,29(5):1020-1030.
12 Pola R. Inflammatory markers for ischaemic stroke. Thromb Haemost,2009, 101(5):800-801.
13 Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke, 2005, 36(6):1316-1329.
14 Rost NS, Biffi A, Cloonan L, et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke, 2012, 43(2):441-445.
15 Woodward M, Lowe GD, Campbell DJ, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke,2005,36(10):2143-2147.
16 Del Zoppo GJ, Levy DE, Wasiewski WW, et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke, 2009, 40(5), 1687-1691.
17 Daniel TL, Scott EK, Jeffrey S, et al. Clinical usefulness of biomarker-based diagnostic test for acute stroke. Stroke, 2009,40(1):77-85.